PARNAX LAB LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116.7 INR | +3.30% |
|
+25.53% | +32.34% |
| 05-30 | Parnax Lab Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 | CI |
| 05-30 | Parnax Lab Limited Approves Reconstitution of Committees of Board of Directors | CI |
| Sales 2022 | 1.63B 19.52M 26.8M | Sales 2023 | 1.68B 20.07M 27.56M | Capitalization | 598M 7.16M 9.83M |
|---|---|---|---|---|---|
| Net income 2022 | 82M 982K 1.35M | Net income 2023 | 86M 1.03M 1.41M | EV / Sales 2022 | 1.08 x |
| Net Debt 2022 | 647M 7.75M 10.64M | Net Debt 2023 | 534M 6.4M 8.79M | EV / Sales 2023 | 0.68 x |
| P/E ratio 2022 |
13.6
x | P/E ratio 2023 |
6.69
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 26.08% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.30% | ||
| 1 week | +25.53% | ||
| Current month | +19.78% | ||
| 1 month | +1.32% | ||
| 3 months | +3.01% | ||
| 6 months | +33.84% | ||
| Current year | +32.34% |
1 week
90.20
118.58
1 month
89.50119.50
Current year
81.00167.90
1 year
55.00167.90
3 years
21.00169.90
5 years
11.65169.90
10 years
11.65169.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 80 | 10-12-06 | |
| Director of Finance/CFO | 69 | 10-12-06 | |
| Compliance Officer | - | 21-06-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 83 | 10-07-31 | |
| Chief Executive Officer | 80 | 10-12-06 | |
| Director of Finance/CFO | 69 | 10-12-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 116.7 | +3.30% | 44,622 |
| 24-06-13 | 112.9 | +4.99% | 3,984 |
| 24-06-12 | 107.6 | +5.00% | 4,717 |
| 24-06-11 | 102.4 | +4.99% | 11,665 |
| 24-06-10 | 97.58 | +4.99% | 10,340 |
Delayed Quote Bombay S.E., June 14, 2024 at 06:00 am
More quotes
Parnax Lab Limited is an India-based holding company. The Company is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations. It is also focused on the trading of pharmaceuticals and medicinal products. The Company operates through dealing in the pharmaceutical formulations segment. It is engaged in developing and delivering huge volumes of oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, special formulations for geriatrics, highly viscous products, suspensions and others. The Companyâs subsidiary is Naxpar Pharma Private Limited.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +32.34% | 16.04M | |
| +0.85% | 92.38B | |
| -3.03% | 37.9B | |
| -10.46% | 33.73B | |
| +74.71% | 27.98B | |
| -13.39% | 15.86B | |
| -1.08% | 13.97B | |
| -11.15% | 11.67B | |
| +169.04% | 10.17B | |
| -50.19% | 10.04B |
- Stock Market
- Equities
- PARNAXLAB6 Stock
